Valink Therapeutics vs Pheon Therapeutics
Pheon Therapeutics
Pheon is an Antibody-Drug Conjugate specialist developing next generation ADCs for a range of hard-to-treat cancers
26 employees · est. 2022 · London, United Kingdom
Valink Therapeutics is the older company (2020 vs 2022).
Side-by-Side Comparison
| Metric | Valink Therapeutics | Pheon Therapeutics |
|---|---|---|
| Founded | ||
| Founded | 2020 older | 2022 |
| Headquarters | ||
| Headquarters | Cambridge, United States | London, United Kingdom |
| Employees | ||
| Employees | 31 | 26 |
| Industry | ||
| Industry | Biotechnology, Health Care, Health and Wellness | Biotechnology, Health and Wellness, Life Sciences |
| Funding Stage | ||
| Funding Stage | Seed | Series B |
| Total Funding | ||
| Total Funding | Not tracked yet | $188.00M |
| Funding Rounds | ||
| Funding Rounds | 2 | 4 |
| Services | ||
| Services | Drug Discovery and Development, Therapeutic Design and Optimization, Biologics Research, Pipeline Development | Development of Antibody-Drug Conjugates, Clinical Development of Cancer Therapies, Research in Oncology |
| Target Customers | ||
| Target Customers | Pharmaceutical Companies, Biotech Researchers, Medical Professionals, Cancer Treatment Facilities, Healthcare Institutions | Healthcare Professionals, Oncologists, Cancer Treatment Centers, Pharmaceutical Distributors |
| Taxonomy | ||
| Taxonomy | Antibody-Drug ConjugatesBsADCsPlatform TherapeuticsOncologySolid TumorsMultivalent Antibodies +7 | Antibody-Drug Conjugates (ADCs)OncologyHard-to-Treat CancersADC DevelopmentMonoclonal AntibodiesProprietary Payload Platform +7 |
| Website | ||
| Website | valinktx.com | pheontx.com |
About Valink Therapeutics
Valink Therapeutics, with its slogan "Making better ADCs," is pioneering the development of novel multivalent bispecific antibody-drug conjugates (bsADCs) designed to revolutionize the treatment of solid tumors and other critical health conditions. The company's innovative approach focuses on non-ob...
About Pheon Therapeutics
Pheon Therapeutics, founded in 2022, is a promising player in the biotechnology, health and wellness, and life sciences sectors, with headquarters in the United Kingdom. The company specializes in developing next-generation Antibody-Drug Conjugates (ADCs) to tackle hard-to-treat cancers, as highligh...
Also comparing in this category
Comparing more than these two?
Get Valink Therapeutics, Pheon Therapeutics and up to nine more competitors side by side in one PDF: team, funding, traffic and every dated move of the last six months. Every company is re-checked on the day you order.
How does Valink Therapeutics compare?
A PDF of Valink Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.
This takes a few seconds: we look beyond our own index too.
Rival Readout
Comparing competitors? We do this properly.
10 rivals, 90 days of dated moves in 7 business days: a ranked list of what matters, each with its source, ending in a 60-minute readout with your team.
Frequently Asked Questions
Compare Valink Therapeutics with someone else
Start typing a company name or domain.
Compiled from the BounceWatch company index. We last looked at Valink Therapeutics on 22 Mar 2026, and Pheon Therapeutics on 29 Apr 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
